|1.||Non-Hodgkin Lymphoma (Lymphosarcoma)
|2.||Hodgkin Disease (Hodgkin's Disease)
01/01/1990 - "The semi-synthetic vinca alkaloid vinzolidine was administered to advanced cancer patients as an intravenous bolus on a three day schedule every 21 days. "
12/01/1985 - "Based on the percentage of survival of tumor colony-forming units in the human tumor cloning system, vinzolidine was shown to have a 26% in vitro response rate with a spectrum of activity across major tumor types. "
07/01/1984 - "Vinzolidine is a new, orally active, semisynthetic vinca alkaloid which shows broad anti-tumor activity against murine tumor test systems. "
01/01/1984 - "Five-day schedule of vinzolidine, an oral vinca alkaloid, in a variety of tumors."
12/01/1985 - "These statistical procedures were applied to results from 54 human tumor specimens that were simultaneously tested against multiple concentrations of the Vinca alkaloid vinblastine and its semisynthetic analogue, vinzolidine. "
|4.||Colorectal Neoplasms (Colorectal Cancer)
|5.||Kaposi Sarcoma (Kaposi's Sarcoma)
01/01/1985 - "Oral vinzolidine as therapy for Kaposi's sarcoma and carcinomas of lung, breast, and colon/rectum."
01/01/1985 - "Vinzolidine, a semisynthetic vinca alkaloid, was studied as oral therapy in 30 patients with Kaposi's sarcoma, non-small cell lung cancer, colorectal cancer, and breast cancer. "
|1.||Vinblastine (Vinblastine Sulfate)
|2.||2'- (2- hydroxyphenyl)- 2'- thiazoline- 4'- carboxylic acid